Sivik Global Healthcare LLC Takes $3.16 Million Position in Merck & Co., Inc. $MRK

Key Points

• Sivik Global Healthcare LLC bought a new stake of 30,000 Merck shares in Q4 valued at approximately $3.16 million.
• Merck beat Q4 expectations with EPS of $2.04 and revenue of $16.4 billion (up 5% YoY), set FY2026 guidance of 5.00–5.15 EPS, and pays a $0.85 quarterly dividend (about a 2.9% yield).
• Merck launched a cash tender offer for Terns Pharmaceuticals to bolster its oncology pipeline and received analyst support (JPMorgan raised its price target to $135), but a lowered offer price for Terns and insider sales have contributed to short‑term share weakness.

Sivik Global Healthcare LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,000 shares of the company's stock, valued at approximately $3,158,000.

Other large investors have also modified their holdings of the company. Darwin Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock valued at $26,000 after buying an additional 216 shares in the last quarter. Barnes Dennig Private Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after buying an additional 266 shares in the last quarter. Evolution Wealth Management Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $31,000. United Financial Planning Group LLC acquired a new stake in shares of Merck & Co., Inc. in the third quarter valued at about $31,000. Finally, Wealth Watch Advisors INC acquired a new stake in shares of Merck & Co., Inc. in the third quarter valued at about $34,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $118.91 on Wednesday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $293.98 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The business has a 50 day simple moving average of $118.21 and a 200-day simple moving average of $103.93.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the previous year, the business earned $1.72 EPS. The business's quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s payout ratio is presently 46.70%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: JPMorgan raised its price target on MRK to $135 and reiterated an Overweight rating, citing upside to the stock — a strong analyst endorsement that supports higher share valuations. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. NYSE: MRK Stock
• Positive Sentiment: Merck has commenced a cash tender offer to acquire Terns Pharmaceuticals, gaining early/mid‑stage oncology assets intended to shore up the pipeline ahead of upcoming patent expiries on key products — a strategically aligned M&A move that investors view as value‑accretive long term. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: Fund commentary and coverage highlight Merck’s strong recent results and its appeal as a consistent dividend payer, reinforcing investor confidence in cash generation and yield support. (Includes JPMorgan’s broader endorsement noted above.) Strong Results Lifted Merck & Co (MRK) in Q4
• Neutral Sentiment: Analyst coverage pieces provide mixed context — some reiterate Merck’s defensive qualities and pipeline strength while flagging upcoming catalysts (earnings on April 30) that could swing sentiment. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Agios Pharma (AGIO)
• Neutral Sentiment: Sector note: Q1 M&A activity in pharma is elevated — Merck’s deal fits a broader industry push to replenish pipelines, which is sector‑positive but increases deal execution and integration risk. Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
• Negative Sentiment: Merck lowered its offer price for Terns after reviewing trial data, which introduces short‑term uncertainty about the deal’s perceived value and may pressure sentiment around the acquisition. Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Negative Sentiment: Merck shares showed a modest intraday decline (~1.3% in recent trade) while broader markets improved, signaling profit‑taking or headline sensitivity around the Terns deal and valuation debate. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether defensive stocks like Merck are overbought may encourage short‑term selling among rotation traders despite positive fundamentals. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Insider Buying and Selling

In other Merck & Co., Inc. news, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. The trade was a 9.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Caroline Litchfield sold 41,997 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer owned 90,192 shares of the company's stock, valued at approximately $10,787,865.12. The trade was a 31.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 over the last 90 days. 0.09% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. TD Cowen upped their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price objective for the company in a research report on Friday, February 13th. Finally, UBS Group upped their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus price target of $127.59.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.